Specify a stock or a cryptocurrency in the search bar to get a summary
Molecure S.A.
MOCMolecure S.A., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis and NASH. It also develops OATD-02, an arginase 1 and arginase 2, which is in Phase I clinical trial for the treatment of cancer; USP7, USP21, and YKL-40 for the treatment of cancer; and Deubiquitinase program. The company was formerly known as OncoArendi Therapeutics S.A. and changed its name to Molecure S.A. in March 2022. Molecure S.A. was founded in 2012 and is headquartered in Warsaw, Poland. Address: Zwirki i Wigury 101, Warsaw, Poland, 02-089
Analytics
WallStreet Target Price
103.08 PLNP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures MOC
Dividend Analytics MOC
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History MOC
Stock Valuation MOC
Financials MOC
Results | 2019 | Dynamics |